Compare SHMD & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SHMD | ARMP |
|---|---|---|
| Founded | 1864 | N/A |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 216.2M | 125.7M |
| IPO Year | N/A | N/A |
| Metric | SHMD | ARMP |
|---|---|---|
| Price | $5.92 | $6.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | ★ 208.8K | 45.6K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $85,165,542.00 | $5,054,000.00 |
| Revenue This Year | N/A | $4.48 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.86 | $0.90 |
| 52 Week High | $6.70 | $16.34 |
| Indicator | SHMD | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 63.97 | 56.96 |
| Support Level | $4.70 | $6.09 |
| Resistance Level | $5.40 | $6.54 |
| Average True Range (ATR) | 0.64 | 0.53 |
| MACD | 0.07 | 0.04 |
| Stochastic Oscillator | 77.36 | 100.00 |
Schmid Group NV is a global supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.